All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Shift Toward Chemotherapy-Free Approaches Redefines Upfront CLL Treatment Selection

August 6th 2025

Kathleen A. Dorritie, MD, discusses 2 clinical scenario cases to showcase differences in the management of newly diagnosed vs relapsed/refractory CLL.

FDA Approves Dordaviprone for Diffuse Midline Glioma

August 6th 2025

The FDA granted accelerated approval to dordaviprone for patients at least 1 year of age with progressive H3K27M-mutated diffuse midline glioma.

Questions Arise As CAR T-Cell Therapy and Bispecific Antibody Use Increase in Relapsed/Refractory Myeloma

August 6th 2025

Prerna Mewawalla, MD, highlights sequencing strategies with CAR T-cell therapy and bispecific antibodies in managing relapsed/refractory multiple myeloma.

Neoadjuvant Pamiparib/Chemo Combo Leads to R0 Resections in Advanced Ovarian Cancer

August 6th 2025

Pamiparib with paclitaxel, carboplatin, and bevacizumab yields high complete cytoreduction rates, manageable safety in advanced ovarian cancer.

FDA Approves Tocilizumab Biosimilar for CAR T-Cell Therapy–Induced CRS

August 6th 2025

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

FDA Accepts NDA for New Formulation of PSMA PET Imaging Agent Piflufolastat F 18 in Prostate Cancer

August 6th 2025

The FDA accepted the NDA seeking the approval of a new formulation of piflufolastat F 18 in prostate cancer.

Olutasidenib is Highly Effective in Certain Patients with Myelodysplastic Syndrome

August 6th 2025

The novel targeted drug olutasidenib has been shown to be effacacious in select patients with MDS.

Rising Early‑Onset CRC Rates in Asia Underscore Global Trend in Incidence and Need for Coordinated Research Efforts

August 6th 2025

Evelyn Y. Wong, MD, discusses an analysis of a multiracial Asian cohort on the incidence of early‑onset colorectal cancer.

OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology

August 6th 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Serum KIM-1 Emerges as Potential Biomarker to Guide Adjuvant Immunotherapy in High-Risk Resected RCC

August 5th 2025

Sumanta Kumar Pal, MD, FASCO, discusses findings from a genomic analysis of patients with high-risk, resected RCC treated with checkpoint inhibitors.

Immunotherapy-Based Trials Challenge Chemotherapy Dominance in MIBC

August 5th 2025

Waddah Arafat, MD, discusses the future clinical implications of the ongoing KEYNOTE-B15/EV-304 trial and the safety profile of the NIAGARA trial regimen.

Rising Incidences, Misconceptions, and Unmet Needs Warrant Awareness for Appendix Cancer

August 5th 2025

Rosario Ligresti, MD, FASGE, discusses the rising incidence of appendix cancer, lack of optimal treatment modalities, and unmet needs for these patients.

Investigation of SENTI-202 in R/R AML Continues After Confirming RP2D

August 5th 2025

A dose-expansion cohort will further evaluate SENTI-202 in relapsed/refractory acute myeloid leukemia.

Intravesical Mitomycin Demonstrates 24-Month Durability in Recurrent Low-Grade, Intermediate-Risk NMIBC

August 5th 2025

Intravesical mitomycin produced a 24-month DOR rate of 72.2% in recurrent low-grade, intermediate-risk NMIBC.

FDA Outlines Next Steps for Development of Eftilagimod Alfa in PD-L1–Negative HNSCC

August 5th 2025

The FDA provided feedback on next steps of development for eftilagimod alfa in PD-L1–negative recurrent/metastatic head and neck squamous cell carcinoma.

Gift Launches $200M Initiative for the Weill Cancer Hub West

August 5th 2025

Matching grant from Weill family creates collaborative research hub, uniting scientists from UCSF and Stanford Medicine to transform cancer care within a decade.

Neoadjuvant Pembrolizumab Could Represent Avenue for Organ Preservation in Nonmetastatic, Unresectable dMMR CRC

August 5th 2025

Neoadjuvant pembrolizumab could represent an avenue for organ preservation in nonmetastatic, unresectable, dMMR colorectal cancer.

FDA Grants Priority Review to Liso-Cel for R/R Marginal Zone Lymphoma

August 4th 2025

The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

BXCL701 Plus Pembrolizumab is Safe and Generates Early Antitumor Activity in Advanced PDAC

August 4th 2025

Benjamin A. Weinberg, MD, FACP, discusses the potential role of BXCL701 plus pembrolizumab in advanced pancreatic ductal adenocarcinoma.

NIAGARA Data Raise Questions About the Role of MVAC in Resectable MIBC

August 4th 2025

Waddah Arafat, MD, discusses the treatment paradigm for MIBC and questions regarding the benefit seen with neoadjuvant chemoimmunotherapy in this setting.